Morphin Hexal (Morphine Sulfate Ph. Eur.)

Morphine sulfate binds to µ‑opioid receptors in the central nervous system, activating them fully. This activation blocks the release of excitatory neurotransmitters, reduces neuronal firing, and enhances descending inhibitory pathways, collectively producing analgesia and sedation.

The dose of Morphin Hexal is individualized. The prescribing clinician determines the appropriate amount, route, and frequency based on the patient’s pain severity, prior opioid exposure, and clinical condition. No standard dosing regimen is provided here.

Safety data for morphine sulfate in pregnancy and lactation are limited. The product is classified as having an unknown pregnancy category. Use only if the potential benefit justifies the potential risk to the fetus or infant, and consult a healthcare professional for guidance.

To request Morphin Hexal, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Morphin Hexal delivers morphine sulfate, a benchmark opioid with well‑characterized efficacy for severe pain. Compared with alternatives such as fentanyl or hydromorphone, morphine has a broader therapeutic window but may require higher doses for equivalent analgesia. Choice depends on patient factors, route of administration, and specific clinical goals.

Morphin Hexal should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from moisture, direct sunlight, and extreme temperature fluctuations to maintain potency and sterility.

Morphin Hexal is supplied as an injectable solution and can be given via epidural, intramuscular, or intrathecal injection. Administration is performed by qualified healthcare professionals following aseptic technique and appropriate dosing guidelines.

The most critical risks include respiratory depression, severe hypotension, adrenal insufficiency, seizures, and anaphylactic reactions. These adverse events require immediate medical attention and may be life‑threatening if not recognized and managed promptly.

Morphin Hexal is contraindicated in patients with known hypersensitivity to morphine or any component of the formulation, in those who have taken monoamine oxidase inhibitors within the past 14 days, and in individuals with significant respiratory compromise where opioid use could exacerbate ventilation failure.